Mark Anthony

Mark Anthony serves as a Contracting Officer responsible for managing complex procurements within the federal healthcare and medical technology sector. He oversees the full lifecycle of acquisitions—from market research and solicitation development to contract award and administration—ensuring compliance with FAR regulations and agency mission objectives. His portfolio centers on high-precision medical devices and pharmaceutical products, requiring technical diligence and stringent quality assurance protocols. Mark plays a critical role in aligning procurement strategy with national health priorities, ensuring timely delivery of essential medical supplies and equipment to support clinical operations. While specific contractor names are not available, Mark maintains a broad network of vendors specializing in medical device manufacturing and pharmaceutical preparation. He engages with both large-capability manufacturers and small businesses capable of meeting stringent FDA and ISO standards. His contracting patterns reflect a preference for established suppliers with proven track records in sterile production, regulatory compliance, and supply chain resilience, fostering long-term partnerships built on reliability and technical competence. Mark demonstrates a strong commitment to small business participation, with 9.3% of his awards designated as Total Small Business Set-Asides under FAR 19.5. Although the majority of his acquisitions are unrestricted, he actively seeks opportunities to include qualified small businesses in the supply chain, particularly those with expertise in surgical instrumentation and diagnostic manufacturing. His socioeconomic contracting approach prioritizes fair competition while maintaining rigorous performance standards. His primary procurement focus lies in NAICS 339112 (Surgical and Medical Instrument Manufacturing) and 339113 (Surgical Appliance and Supplies Manufacturing), reflecting deep expertise in Class II and III medical devices. He also regularly procures pharmaceutical preparations and in-vitro diagnostic substances, demonstrating technical fluency in sterile processing, biocompatibility standards, and regulatory pathways. Mark’s domain knowledge ensures that acquisitions meet clinical requirements while adhering to federal procurement integrity principles.